Physician profile

Gregory M Koshkarian

Cardiovascular Disease · Tucson, AZ

NPI 1164425096

$12,705.02

in general payments reported to CMS, 2019-2025

46 companies · $1,968 in 2025

The $1,968 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

See the full distribution for Cardiovascular Disease

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,267.70
Education$0.83

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,858.96 2019-2025
Pfizer INC. $864.51 2019-2025
Cvrx, INC. $825.42 2020-2025 Barostim Neo System
Janssen Pharmaceuticals, INC $688.12 2019-2024 Xarelto
Amgen INC. $686.49 2019-2025 Repatha
Boston Scientific Corporation $670.46 2019-2025 General - Ep
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $601.76 2019-2025 Lifevest
Boehringer Ingelheim Pharmaceuticals, INC. $524.02 2019-2025 Jardiance
Astrazeneca Pharmaceuticals LP $497.11 2019-2025 Farxiga, Wainua, Lokelma
Merck Sharp & Dohme LLC $473.57 2021-2025 Verquvo
Actelion Pharmaceuticals US, INC. $404.41 2022-2024 Opsumit, Uptravi
Amarin Pharma, INC. $331.78 2019-2022
Alnylam Pharmaceuticals INC. $328.22 2022-2025 Amvuttra
Impulse Dynamics (USA) INC. $302.57 2021-2024 Optimizer, Optimizer
Abbott Laboratories $293.11 2019-2022
Show all 45 companies
CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $292.32 2019-2025 Camzyos, Eliquis
Sanofi-Aventis U.S. LLC $269.79 2019-2024
Kestra Medical Technology Services, INC. $261.37 2024-2025 Assure Wcd
Edwards Lifesciences Corporation $248.04 2023-2025 Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Lilly USA, LLC $225.49 2021-2025 Zepbound, Mounjaro
Akcea Therapeutics, INC. $202.67 2019
Corcym INC $188.54 2024 Perceval
Silk Road Medical, INC. $188.31 2020
Esperion Therapeutics, INC. $149.85 2020-2022
Zoll Respicardia, INC. $133.93 2021
Inspire Medical Systems, INC. $117.16 2022
Abiomed $105.71 2019-2022
Kiniksa Pharmaceuticals, LTD. $105.56 2021-2023 Arcalyst
Bardy Diagnostics, INC. $105.00 2019-2020
Bayer Healthcare Pharmaceuticals INC. $100.24 2024-2025
Bridgebio Pharma, INC. $92.84 2025 Attruby
Kiniksa Pharmaceuticals International, Plc $79.78 2024 Arcalyst
Medtronic Vascular, INC. $77.91 2019
Baxter Healthcare $69.45 2023 Hillrom - Carnation Ambulatory Monitor
Tactile Systems Technology INC $64.12 2019
Inari Medical, INC. $45.74 2024 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Nevro Corp. $43.93 2024 Senza
Philips North America LLC $40.00 2019
Kowa Pharmaceuticals America, INC. $31.24 2019-2020
Lexicon Pharmaceuticals, INC. $26.51 2023 Inpefa
Novo Nordisk INC $25.20 2025 Wegovy
Terumo Medical Corporation $21.67 2024 Azur Cx Detachable
Regeneron Healthcare Solutions, INC. $21.30 2019
Scpharmaceuticals INC. $20.01 2023
Travere Therapeutics, INC. $0.83 2023 Cholbam

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$3,633.90 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gregory M Koshkarian

$12,705.02

in general payments reported 2019-2025

Years
2019-2025
Top company
Eli Lilly and Company
Context
The $1,968 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/279621/gregory-m-koshkarian

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.